Complement Regulation to Undo Systemic Harm in Preeclampsia
Complement Regulation to Undo Systemic Harm in Preeclampsia
This is a Phase II, single arm, open-label study to determine if treatment with eculizumab
 prolongs pregnancy compared to historical controls in women with preeclampsia between 23-30
 weeks gestation.
The purpose of this study is to determine if eculizumab is an effective treatment to prolong
 pregnancy in women with preeclampsia, compared to a historical control group of women that
 received standard of care alone. Eligible subjects will be women with preeclampsia before 30
 weeks gestation, who have been deemed suitable for prolongation of pregnancy.

 The primary research procedure is administration of the study drug, eculizumab, by
 intravenous infusions weekly for four weeks, then every other week. Eculizumab is approved by
 the FDA for the treatment of women with atypical hemolytic uremic syndrome and paroxysmal
 nocturnal hemoglobinuria and is frequently used in pregnant women with these disorders.
 However, eculizumab is considered investigational in this study because it has not been
 approved by the FDA for use in patients with preeclampsia. Subject participation will last
 approximately 8-12 weeks on average, and the study drug will be continued until 48 hours
 after delivery in the treatment arm. All subjects will be followed at 2 weeks and 6 weeks
 after delivery to assess maternal and neonatal outcomes. A later visit may be required to
 complete the meningococcal vaccine schedule.

 The investigators believe that eculizumab will prolong pregnancy in women with preeclampsia
 diagnosed before 30 weeks gestation with overactive complement. As there is no effective
 treatment for preeclampsia other than delivery currently, women with preeclampsia before 30
 weeks gestation are managed using a "watch and wait" approach (i.e., expectant management).
 Due to the unpredictable nature of preeclampsia, expectant management places mother and child
 at significant risk until delivery occurs. Eculizumab may be an improvement over current
 standard of care as it provides a treatment option for patients who would otherwise be
 managed with expectant management alone. If the study aims are achieved, eculizumab will
 emerge as an effective treatment option for women with preeclampsia.
Inclusion criteria:

 1. Provision of signed and dated informed consent form

 2. Stated willingness to comply with all study procedures & availability for study
 duration

 3. Biologically female, aged ≥13, body weight ≥40kg

 4. Diagnosed with preeclampsia between 23-29+6/7 weeks gestation, by following criteria:

 1. Blood pressure ≥160 mmHg systolic or ≥110 mmHg diastolic OR

 2. Blood pressure ≥140 mmHg systolic or ≥90 mmHg diastolic and at least one of the
 following

 i. Proteinuria (spot protein/creatinine ≥0.3mg/mg or 24Hr protein ≥300 mg) ii.
 Platelet count <100,000/μl iii. Aspartate or alanine transaminase >2x upper limit of
 normal iv. Creatinine >1.1 mg/dl or oliguria v. Pulmonary edema

 5. Ability to take intravenous medication and be willing to adhere to the eculizumab
 regimen

 6. Ability to receive meningococcal vaccine and be willing to adhere to antibiotic
 regimen

 Exclusion Criteria:

 An individual who meets any of the following criteria prior to enrollment will be excluded
 from participation in this study:

 1. Known allergic reactions eculizumab or meningococcal vaccine

 2. Febrile illness within prior 2 weeks

 3. Treatment with another investigational drug within previous 6 months

 4. Inpatient expectant management for preeclampsia >72 hours prior to enrollment

 5. Fetal contraindication to expectant management of pregnancy

 6. Platelet count <50,000/μl

 7. Diagnosis of hemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome

 -  Must meet all of the following criteria to be excluded: LDH >600 U/L, platelet
 count < 100,000/μl, AST >2x upper limit of normal, ALT >2x upper limit of normal

 8. Diagnosis of Eclampsia

 9. Diagnosis of Placental abruption

 10. Intrauterine fetal demise

 11. Coagulopathy (INR ≥ 1.5)

 12. Fibrinogen <200 mg/dl

 13. Persistent, severe headache unresponsive to medications

 14. Persistent, severe visual disturbances

 15. Persistent, severe epigastric or RUQ pain unresponsive to medications

 16. Diagnosis of Systemic lupus erythematosus

 17. Diagnosis of Anti-phospholipid antibody syndrome

 18. Diagnosis of Atypical hemolytic uremic syndrome

 19. Diagnosis of Paroxysmal nocturnal hemoglobinuria

 20. Known complement deficiency

 21. Diagnosis of Venous thromboembolism active or within 6 months of enrollment

 22. Diagnosis of Human immunodeficiency virus (HIV)

 23. Diagnosis of Hepatitis C virus (active viremia)

 24. Diagnosis of Cancer (not in remission)

 25. History of Solid organ transplant

 26. Systemic viral or bacterial infection (active, untreated)

 27. Active use of eculizumab at time of enrollment

 28. Contraindication to eculizumab treatment or complement system blockade

 29. Contraindication to meningococcal vaccine

 30. Body weight <40kg

 31. Age <13

 32. Neutropenia (<1500/mm3)

 33. Gonorrhea, chlamydia, or syphilis in current pregnancy

 34. Illicit substance use in current pregnancy

 35. Currently homeless or incarcerated

 36. Alcoholism

 37. Liver cirrhosis

 38. Insulin dependent diabetes

 39. Active use of immunosuppressive therapies, other than use of corticosteroids for fetal
 lung maturity

 40. Use of prophylactic or therapeutic heparin, or low molecular weight heparin, in
 pregnancy for hypercoagulable condition